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Abstract
Objective: To evaluate the prevalence of hepatitis A virus antibodies in HIV-exposed and/or HIV-infected children
and adolescents.
Methods: Between September 1996 and August 2002, 352 patients (200 exposed, but not HIV-infected and 152
HIV exposed and infected) were included in this study. These children and adolescents (age ranged between 1 and
14 years) were all followed up at the Pediatric AIDS Clinic of the Federal University of Sªo Paulo (UNIFESP) and had
anti-HAV antibodies determined by a commercially available ELISA method (tests for total anti-HAV antibodies and
specific IgM antibodies) (Dia Sorin and Radim). Statistical analyses were done with chi-squared and t test.
Results: The prevalence of hepatitis A virus antibodies in HIV-infected and HIV-exposed, but uninfected patients
was 34% and 19.7%, respectively. We noticed that in the age range between 2 years and 10 years, the group of HIV-
infected children presented a higher prevalence of hepatitis A virus antibodies (35.5%) than the group of uninfected
children (16.7%) (p = 0.005). In the HIV infected group, children from B and C categories had a prevalence of hepatitis
A virus antibodies (40.5%) higher than N and A categories (24.1%) (p = 0.042). Mean age did not differ when children
from B and C categories were compared with N and A categories (5.18 and 5.66 years, respectively) (p = 0.617).
Conclusions: The prevalence of hepatitis A virus antibodies in HIV exposed and/or infected children and
adolescents between 1 and 14 years old was 26%. Considering the possibility of HIV infection aggravation when
associated with hepatitis A virus infection, we suggest that hepatitis A virus inactivated vaccine should be administered
to these patients.
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ORIGINAL ARTICLE
Introduction
Hepatitis A is an acute viral disease classically
characterized as benign. Transmission occurs via the
fecal-oral route, which can be person to person or via
contaminated water or food.
In children, the disease is generally asymptomatic or
has mild clinical manifestations, in contrast with adults
when the course of the disease is predominantly
symptomatic. The probability of developing jaundice
increases with age: it is 7% between 0 and 4 years, 37%
from 5 to 9, 70% from 10 to 17 and 85% from 18 years
of age onwards.1 Rarely fatal, hepatitis A does not
progress with carriers or chronic forms of the disease; in
adults, there may be more severe developments, with a
greater proportion of prolonged and polyphasic forms of
the disease and a greater frequency of the cholestatic and
fulminating forms of the disease, the last one is extremely
serious.
Fulminating hepatitis A is a rare event, occurring in
something around 0.008% of the Hepatitis A cases.2 The
following factors that can be of importance in the
development of liver failure in pediatric sufferers of
hepatitis A cases: dimension of inoculate, genetic back-
ground of the host and the presence of concurrent
infections.2 Despite the rarity of the severe form of
206  Jornal de Pediatria - Vol. 81, No.3, 2005 Prevalence of hepatitis A virus antibodies in HIV infected  GouvŒa AFTB et alii
hepatitis A, 20% of pediatric liver transplantations in
Argentina are the result of hepatitis A.3
Some studies have suggested that acute hepatitis A
acts as a possible trigger for the development of
autoimmune hepatitis in susceptible individuals: people
who exhibit a defect in T lymphocyte suppressors may
develop chronic autoimmune hepatitis when exposed to
the hepatitis A virus (HAV).4,5
The virus for acquired immunodeficiency (HIV) can
impact on the clinical course of hepatitis A,6,7 while, on the
other hand, HAV-infection may be linked with a prolonged
increase in the HIV-viral load.8,9
Concerned by the existence of this co-infection in our
pediatric population, and accepting that the base liver
disease (which, in such children, may equally be the
consequence of HIV itself, or of opportunistic infections
and anti-retroviral therapy) increases the risk of
fulminating hepatitis, we decided to investigate the
frequency of HAV infection among children exposed to
and/or infected by HIV.
Patients and methods
This research project was approved by the Committee
for Ethics in Research at the Hospital Sªo Paulo/Universidade
Federal de Sªo Paulo (UNIFESP). The study investigated the
medical records of 352 children born to HIV seropositive
mothers and followed-up at the Division of Pediatric Infectious
Disease Clinic (CEADIPE) at the UNIFESP/EPM in Sªo Paulo
during the period from September 1996 to August 2002.
Data from the medical record (identification, age, HAV
serology, clinical and immunological classification of HIV
infection) were stored in Microsoft Excel 97.
HIV-infected children were classified clinically and
immunologically according to the CDCs 1994 standards:10
clinical categories: N (absence of AIDS symptoms), A
(mild symptoms), B (moderate symptoms), C (severe
symptoms). Immunological categories: 1 (no immune
system suppression according to CD4 T lymphocyte
counts), 2 (moderate immune system suppression), 3
(severe immune system suppression).
A qualitative test for total anti-HAV antibodies was
performed as part of routine workup using a laboratory test
that is commercially available in our country. The test
employs the competitive enzyme immunoassay (ELISA)
technique and is manufactured by DiaSorin and Radim, both
Italian. Results were defined as positive, negative or
borderline according to positive and negative controls. A
cutoff value was calculated, below which the sample was
classified as positive and above which negative. Tests
whose absorbance was within the gray area, which is more
or less 20% of the cutoff value, were defined as borderline.
Antibody levels greater than 20 mlU/ml were considered
protective. Qualitative IgM antibody detection was performed
by means of the immunoenzymatic capture assay (IEMA) or
sandwich ELISA. These tests were all performed at the
Central Laboratory at the Hospital Sªo Paulo.
Statistical analysis used the chi-square test to compare
the age groups of the two study groups and the t test in
order to compare the mean age of patients in each of the
clinical categories within the HIV-infected group of children.
The significance level employed was 0.05.
Results
The initial study population consisted of 352 patients,
of whom 177 (50.3%) were female and 175 (49.7%) were
male.
Seventeen children were excluded as they exhibited
borderline or indefinite serology for HAV: five (3.28%)
patients in the HIV group (HIV) and 12 (6%) patients in the
group of uninfected children (S/R). Thus, the number of
children evaluated in the HIV group was 147 and in the S/R
group 188 children, making a total of 335 children. The
mean age of the HIV group was 4.6 years and it was 2.5
years in the S/R group (p < 0.0001). The majority of the
children in the HIV group were female and in the S/R group
the majority were male (p = 0.011) (Table 1).
It is important to point out that none of the children
analyzed in this study had been given vaccine against
HAV. Furthermore, none of the children had been given
immunoglobulin or blood products during the previous 6
months.
The prevalence of total HAV antibodies was greater in
the HIV group (p = 0.003) when compared with the SR group
(Table 2). HIV-infected children with presented greater
seroprevalence in comparison with the group of HIV
uninfected children in all of the age groups studied (Table 3)
and this difference was statistically significant for the 2 to
10 year age group (p = 0.005).
Fifty out of 147 (34%) HIV-infected patients (34%)
presented positive serology for HAV. We stratified the
group according to clinical and immunological criteria
(CDC, 1994)10 applied at the point of collection for HAV
serology. Children in clinical categories B and C (moderately
and severely symptomatic) were taken together and
Table 1 - Characteristics of patients in the HIV and S/R groups
according to age and sex
* p- value obtained with the t-test for unequal variance.
† p- value obtained with the chi-square test.
S/R = serum-reverted.
Group
HIV S/R p
Age (years)
Mean 4.6 2.5 < 0.0001 *
Standard deviation 3.1 1.9
Median 3.4 1.7
Sex n (%) n (%)
Female
Male 84 (57.1) 81 (43.1) 0.011 
63 (42.9) 107 (56.9)
Jornal de Pediatria - Vol. 81, No.3, 2005  207
compared with those in the clinical categories A and N
(oligosymptomatic and no symptoms). For immunological
c lass i f icat ion chi ldren c lassi f ied as 1 (no
immunosuppression) were grouped with children classified
as 2 and 3 (moderate immunosuppression and severe
immunosuppression). We found that there was no
association between immunological category and the
presence of anti-HAV antibodies, although HIV-class B
and C children presented a greater proportion of HAV
seropositive children (40.5%) when compared with HIV-
class N and A ones (24.1%) (p = 0.042) (Table 4).
Table 4 - Distribution of HIV-infected patients according to
clinical and immunological categories applied at the
moment of collection for HAV serology
Table 3 - Sample stratification by age range of children with
positive serology for hepatitis A virus (second group)
Group
Age range HIV S/R p *
(years) (n = 147) (n = 188)
1-2 6/24 (25%) 24/110 (21.8%) 0.735
2-10 39/110 (35.5%) 13/78 (16.7%) 0.005
> 10 5/13 (38.5%) 
* p-value obtained with the chi-square test.
S/R = serum-reverted.
Obs.: Immunological category information of two patients not found.
* p = chi-square.
Presence of anti-HAV
antibodies
Category of
HIV infection Positive Negative p *
Clinical
N+A 14 (24.1%) 44 (75.9%)
B+C 36 (40.5%) 53 (59.5%) 0.042
Immunological
1 9 (28.1%) 23 (71.9%)
2+3 41 (36.3%) 72 (63.7%) 0.392
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It is worth noting that the mean age of HAV seropositive
children was similar among those in the HIV group classed
clinically as N and A (mean of 5.7 years and standard
deviation of 2.6 years) and those classed clinically as B
and C (mean of 5.2 years, and a standard deviation of 3.2
years) (t test = 0.617).
Discussion
Within the general population, the prevalence of HAV
antibodies varies according to age, local epidemiological
conditions, socioeconomic status and basic sanitation in
different regions worldwide.11-15 Research undertaken in
Brazil show that the prevalence of HAV antibodies is directly
proportional to age and inversely proportional to socio-
economic level.16-18
In our research, the prevalence of antibodies against
HAV among the 335 HIV exposed and/or infected children
tested was 26% (Table 2). These data are compatible with
figures published by Ferreira et al.19 in 2002, studying
children and adolescents with chronic liver disease in the
State of Rio Grande do Sul.
The greater prevalence of HAV antibodies among infected
children (34%) in comparison with the uninfected ones
(19.7%), was probably the consequence of differences in
age between the two groups, since the mean ages of the two
populations was distinct (4.6 years in the HIV group HIV and
2.5 years for the uninfected group) (Table 1). With the
intention of obtaining comparable groups, we excluded
children between 1 and 2 years old from the HIV group (due
to the significant difference in the number of patients
between the two groups in this age group) and also those
aged more than ten years (since there were no children in
this age range in the uninfected group). Comparing the two
groups of children aged 2 to 10 years, we observed that HAV
seroprevalence was 35.5% for the HIV group, and 16.7% for
the S/R group, reinforcing the greater HAV seroprevalence
in the HIV group. Considering that the prevalence of HAV
antibodies tends to increase with age, we compared the two
study groups by means of stratification by age group (Table
3). While the prevalence of antibodies against HAV tends to
be greater among the group of patients infected by HIV
when compared with the group of uninfected children, the
difference was statistically significant only in the age group
from 2 to 10 years of age.
Focaccia et al.,18 evaluating the general population of
Sªo Paulo in 1998, found that the prevalence of HAV
antibodies was 21.9% between 2 and 9 years of age. The
difference in relation to the pediatric HIV-infected population
in our study may be the consequence of the socio-economic
level of the two populations evaluated. Focaccia et al.18
studied the general population with individuals belonging to
all socioeconomic classes, in contrast with the majority of
children who attend the Pediatric Infectious Disease Clinic
are from less favored economic classes according to the
ANEP.20
It is interesting to observe that children exhibiting
moderate and severe HIV symptomology (categories B and
Table 2 - Prevalence of total hepatitis A virus antibodies (second
group)
Group
Presence of IgG HIV S/R Total
(n = 147) (n = 188)
Positive 50 (34%) 37 (19.7%) 87 (26%)
Negative 97 (66%) 151 (80.3%) 248 (74%)
S/R = serum-reverted.
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C) also exhibited greater prevalence rates of HAV antibodies
when compared with children without symptoms or with
mild symptoms (categories N and A) (chi-square, p = 0.042)
(Table 4). Considering that this greater prevalence might be
related to the greater age of the moderately and severely ill
patients, we compared the mean ages of the two groups and
found that they were similar (5.7 years for the N and A group
and 5.2 years for the B and C group, p = 0.617). We did not
find any explanation for this difference in seroprevalence.
In relation to HIV-infected children aged 10 to 14 years,
seroprevalence was compatible with data from Focaccia et
al..18 Considering that the seroprevalence of HAV antibodies
among HIV-infected children increased with age up to 10
years and then dropping among those from 10 to 14 years
old, we could infer that these patients might lose their HAV
antibodies during adolescence. Our results for patients over
ten should be treated with caution, since the sample for this
age range was small.
Taking into consideration the fact that moderately and
severely HIV-symptomatic patients presented greater HAV
seroprevalence and that this group of children is more
subject to opportunist infections and liver toxicity due to the
anti-retroviral drugs they are given, we emphasize the need
to prevent liver damage by means of vaccinal prophylaxis
for all HIV-infected patients.
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